Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Mitchell Boxer, MD

Assistant Clinical Professor
Albert Einstein College of Medicine
Member of the Healthcare Council

Mitchell Boxer, MD, is Director of the Adult Allergy Section at Long Island Jewish Medical Center and Assistant Clinical Professor at Albert Einstein Medical College. Dr. Boxer completed his fellowship at Northwestern University Medical College and has expertise in a wide range of allergic and immunologic diseases, including asthma, chronic sinusitis, allergic rhinitis, drug allergies and immunoglobulin deficiencies (This is me - Update Profile)


Employment History
Unspecified - present Assistant Clinical Professor
Albert Einstein College of Medicine
Unspecified - present Director of Adult Allergy Section
Long Island Jewish Medical Center

GLG Study Groups with Mitchell Boxer, MD(?)

View All Study Groups with Mitchell Boxer, MD

GLG NewsSM Analyses by Mitchell Boxer, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Another nasal corticosteroid | 08-30-2007
Analysis of: Collegium Pharmaceutical provides update on development of its nasal inhaled steroid for allergic rhinitis | www.pipelinereview.com
Author: Mitchell Boxer, MD, Assistant Clinical Professor, Albert Einstein College of Medicine

A new nasal corticosteroid being released by another pharmaceutical company

Xyzal approval | 08-30-2007
Analysis of: New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com
Author: Mitchell Boxer, MD, Assistant Clinical Professor, Albert Einstein College of Medicine

Zyrtec will soon be available over the counter and this new product will attempt to keep the antihistamine market share for Sanofi-Aventis - although Zyrtec is presently manufactured by Pfizer.  The antihistamine market is quite large and the OTC versus prescription situation is making this problematic...

intranasal antibiotics for chronic sinusitis | 04-23-2007
Analysis of: FDA Approves Fast Track Designation for Naryx Pharma’s Product for Chronic Sinusitis | www.naryxpharma.com
Author: Mitchell Boxer, MD, Assistant Clinical Professor, Albert Einstein College of Medicine

I have not found nebulized antibiotic therapy to be of great success in patients with chronic sinusitis.  There are already a few pharmacies that have formulated an array of nebulized antibiotics and I have tried them in a few patients with no success.   

Xolair apprehension | 02-27-2007
Analysis of: FDA Orders Black Box Anaphylaxis Warning for Omalizumab (Xolair) | www.medpagetoday.com
Author: Mitchell Boxer, MD, Assistant Clinical Professor, Albert Einstein College of Medicine

There is a concern about anaphylaxis secondary to Xolair administration and this may result in longer waiting times after the administration of the drug.

GLG InstituteSM Seminars with Mitchell Boxer, MD(?)

 
Mitchell Boxer, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Mitchell Boxer, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics